Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DR. REDDYS LAB   MYLAN
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-23
MYLAN
Dec-18
DR. REDDYS LAB/
MYLAN
5-Yr Chart
Click to enlarge
High Rs4,6563,967-   
Low Rs3,7882,184-   
Sales per share (Unadj.) Rs1,481.41,825.4-  
Earnings per share (Unadj.) Rs270.749.6-  
Cash flow per share (Unadj.) Rs345.7391.3-  
Dividends per share (Unadj.) Rs40.000-  
Avg Dividend yield %0.90-  
Book value per share (Unadj.) Rs1,389.61,974.7-  
Shares outstanding (eoy) m166.53514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x2.81.7 169.2%   
Avg P/E ratio x15.662.0 25.1%  
P/CF ratio (eoy) x12.27.9 155.4%  
Price / Book Value ratio x3.01.6 195.1%  
Dividend payout %14.80-   
Avg Mkt Cap Rs m703,0391,582,214 44.4%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m46,4660-   
Avg. sales/employee Rs Th026,833.1-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0728.6-  
INCOME DATA
Net Sales Rs m246,697939,158 26.3%  
Other income Rs m10,5550-   
Total revenues Rs m257,252939,158 27.4%   
Gross profit Rs m63,860243,019 26.3%  
Depreciation Rs m12,502175,847 7.1%   
Interest Rs m1,42845,170 3.2%   
Profit before tax Rs m60,48522,002 274.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m15,412-3,500 -440.3%   
Profit after tax Rs m45,07325,502 176.7%  
Gross profit margin %25.925.9 100.0%  
Effective tax rate %25.5-15.9 -160.2%   
Net profit margin %18.32.7 672.8%  
BALANCE SHEET DATA
Current assets Rs m203,161524,425 38.7%   
Current liabilities Rs m85,721382,364 22.4%   
Net working cap to sales %47.615.1 314.7%  
Current ratio x2.41.4 172.8%  
Inventory Days Days7984 94.8%  
Debtors Days Days10793 114.9%  
Net fixed assets Rs m112,638182,181 61.8%   
Share capital Rs m833500 166.6%   
"Free" reserves Rs m230,5710-   
Net worth Rs m231,4041,015,998 22.8%   
Long term debt Rs m1,2781,096,588 0.1%   
Total assets Rs m315,7992,725,301 11.6%  
Interest coverage x43.41.5 2,915.5%   
Debt to equity ratio x01.1 0.5%  
Sales to assets ratio x0.80.3 226.7%   
Return on assets %14.72.6 567.8%  
Return on equity %19.52.5 776.0%  
Return on capital %26.63.2 836.8%  
Exports to sales %52.20-   
Imports to sales %16.80-   
Net fx Rs m87,3190-   
CASH FLOW
From Operations Rs m58,875195,157 30.2%  
From Investments Rs m-41,373-100,875 41.0%  
From Financial Activity Rs m-26,861-90,916 29.5%  
Net Cashflow Rs m-9,0731,617 -561.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 83.34 Rs / USD

Compare DR. REDDYS LAB With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare DR. REDDYS LAB With: EVEREST ORGANICS  BACIL PHARMA  VINEET LABORATORIES  COLINZ LABOR  ISHITA DRUGS  



Today's Market

Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising(Closing)

After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.